Clinical Trials Browser

Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Phase 2 Active not recruiting

90 enrolled

Gynecologic

Endometrial Neoplasms

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

Phase 4 Active not recruiting

134 enrolled

Breast

Breast Neoplasms

NCT01872260 2026-01-30

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Phase 1/2 Active not recruiting

255 enrolled

Breast

Breast Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Phase 1 Active not recruiting

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT04964934 2026-01-16

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Phase 2 Active not recruiting

24 enrolled

Breast

Breast Neoplasms

NCT03090165 2026-01-02

Ribociclib and Bicalutamide in AR+ TNBC

Phase 1/2 Active not recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

Phase 2 Active not recruiting

51 enrolled 19 charts

Cystadenocarcinoma, Serous

NCT03285412 2025-12-22

LEADER

Phase 2 Active not recruiting

120 enrolled

Breast

Breast Neoplasms

Clinical Trials

RosaLEE

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

FELINE

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

NATALEE

KontRASt-03

Ribociclib (LEE011) Rollover Study for Continued Access

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

Roll-over Study to Allow Continued Access to Ribociclib

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

SERENA-6

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Ribociclib and Bicalutamide in AR+ TNBC

Ribociclib and Letrozole Treatment in Ovarian Cancer

LEADER